Here's a look at some of the latest news regarding ophthalmic drugs and therapies from the past week.
- EyeGate Pharmaceuticals, Inc. enrolled the first patient in its Phase 2b clinical trial of its EGP-437 combination product. The EyeGate® II Delivery System and EGP-437 combination product is reportedly being evaluated for the treatment of pain and inflammation in patients having undergone cataract surgery with implantation of a monofocal posterior chamber IOL (intraocular lens).
- Avedro, Inc. announced the publication of one-year safety and efficacy data from the randomized, controlled pivotal Phase 3 clinical trials that supported the FDA approval of the second clinical indication for Avedro’s Photrexa® Viscous (riboflavin 5’-phosphate in 20% dextran ophthalmic solution), Photrexa® (riboflavin 5’-phosphate ophthalmic solution) and KXL® System for the treatment of corneal ectasia following refractive surgery. Results from the clinical trials, in which a reported 179 patients with corneal ectasia were treated at multiple U.S. sites, were published in Ophthalmology®, the journal of the American Academy of Ophthalmology.
- Spark Therapeutics submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for LUXTURNA™, the proposed trade name for voretigene neparvovec — an investigational, one-time gene therapy for the treatment of patients with vision loss due to Leber congenital amaurosis or retinitis pigmentosa caused by confirmed biallelic RPE65 mutations.
- Aerie Pharmaceuticals, Inc. has entered into a collaborative research, development and license agreement with DSM. The research collaboration agreement reportedly includes an option to license DSM's bioerodible polymer implant technology for evaluating its application to the delivery of certain Aerie compounds, initially focused on retinal diseases.
- And Bio-Tissue, Inc. has formed a strategic agreement with Scope to bring Bio-Tissue’s PROKERA® biologic corneal bandage devices to the UK and Irish eye care professionals market.
Like what you read? Follow OphthalmologyWeb to keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.